Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9,895 JPY | +0.87% | +1.47% | -23.44% |
Mar. 06 | Shares in Japan's Ain soar after activist fund Oasis buys 9.6% stake | RE |
Feb. 28 | Aeon Co. Plans to Merge Japan Drugstore Unit Welcia With Rival Tsuruha -- 2nd Update | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.43 for the 2024 fiscal year.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company is highly valued given the cash flows generated by its activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.44% | 3.06B | D | ||
-11.64% | 3.62B | D+ | ||
-0.09% | 3.36B | D- | ||
+7.46% | 2.59B | C+ | ||
-9.26% | 1.75B | - | ||
+9.30% | 1.35B | - | - | |
-20.60% | 957M | - | ||
-38.42% | 704M | - | - | |
-0.53% | 450M | - | D+ | |
-1.85% | 370M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3391 Stock
- Ratings Tsuruha Holdings Inc.